	US 12,422,434 B2
	Systems and processes to screen for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) of 2019 (COVID-19)
Melicia R. Gainey, Columbus, OH (US); and Dalia Natour, Columbus, OH (US)
Filed by BATTELLE MEMORIAL INSTITUTE, Columbus, OH (US)
Filed on Feb. 14, 2024, as Appl. No. 18/441,086.
Application 18/441,086 is a division of application No. 17/337,022, filed on Jun. 2, 2021, granted, now 11,921,114.
Claims priority of provisional application 63/041,551, filed on Jun. 19, 2020.
Claims priority of provisional application 63/033,276, filed on Jun. 2, 2020.
Prior Publication US 2024/0192212 A1, Jun. 13, 2024
Int. Cl. G01N 33/569 (2006.01); C07K 16/10 (2006.01); G01N 33/543 (2006.01); C12N 5/071 (2010.01)

CPC G01N 33/56983 (2013.01) [C07K 16/1003 (2023.08); G01N 33/543 (2013.01); C07K 2317/20 (2013.01); C12N 5/0686 (2013.01); C12N 2523/00 (2013.01); G01N 2333/165 (2013.01)]

11 Claims

1. A process for performing microneutralization assays to quantify neutralizing antibodies to viruses, the process comprising:

coating a plate with a monolayer of Vero E6 cells;

inoculating the coated plate with a serum-included inoculum, the serum-included inoculum comprising:

serum from a patient, the serum being diluted; and

a virus, the virus being Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-COV-2);

incubating the inoculated plate;

fixing the Vero E6 cells plate;

diluting a primary antibody, the primary antibody being selected from the group consisting of:

Mouse Species Coronavirus (COVID-19, MERS, and SARS-COV NP) Antibody, Catalog Number HM1056 (“E3”);

E3 in combination with Mouse Species Coronavirus (COVID-19, MERS, and SARS-CoV NP) Antibody, Catalog Number HM1057 (“E1”); and

Mouse Species Anti-SARS-Cov-2 NP mAb, clone 4B21, Catalog Number CABT-CS027 (“C4”) in combination with Mouse Species Anti-SARS-Cov-2 NP mAb, clone 4B21, Catalog Number CABT-CS026 (“C5”);

adding the diluted primary antibody to the fixed plate;

incubating the plate having the diluted primary antibody;

washing the plate having the diluted primary antibody;

adding a secondary antibody to the plate;

incubating the plate having the secondary antibody;

washing the plate having the secondary antibody;

applying 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) solution to the plate;

applying a stop solution to the plate;

reading the optical density of the plate; and

determining whether the optical density is greater than approximately 0.7.